Quarterly Reports and Events - Research Report on Mettler-Toledo, Galena Biopharma, Achillion, Wright Medical, and OXiGENE Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 15, 2013 NEW YORK, November 15, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Mettler-Toledo International Inc. (NYSE: MTD), Galena Biopharma, Inc. (NASDAQ: GALE), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Wright Medical Group Inc. (NASDAQ: WMGI), and OXiGENE, Inc. (NASDAQ: OXGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Mettler-Toledo International Inc. Research Report On November 7, 2013, Mettler-Toledo International Inc. (Mettler-Toledo) released its Q3 2013 results. Mettler-Toledo registered net sales of $591.7 million in Q3 2013, up 2.3% YoY. The Company posted net earnings of $74.3 million in Q3 2013, up 3.0% YoY. Mettler-Toledo reported diluted EPS of $2.43 in Q3 2013, up 6.6% YoY. Commenting on the results, Olivier Filliol, President and CEO of Mettler-Toledo, said, "We saw an improvement in market conditions in Europe while customer demand in the Americas remains solid. In China, soft market demand, continued credit constraints in specific segments of our customer base and the exit of certain industrial product lines resulted in a sales decline. However, we generated good EPS growth as we benefitted from our various margin improvement and cost control initiatives. Cash flow was also very strong in the quarter." The Full Research Report on Mettler-Toledo International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/ac69_MTD -- Galena Biopharma, Inc. Research Report On November 6, 2013, Galena Biopharma, Inc. (Galena Biopharma) released its Q3 2013 results. The Company posted net loss of $9.3 million in Q3 2013, compared to net loss of $6.3 million in Q3 2012. Galena Biopharma reported basic and diluted net loss per share of $0.11 in Q3 2013, compared to basic and diluted net loss per share of $0.09 in Q3 2012. Mark J. Ahn, Ph.D., President and CEO of Galena Biopharma, stated, "Our commercial success to date with Abstral® has been very encouraging and we are excited to report initial revenues ahead of schedule. With our sales force and commercial organization fully deployed, we continue to make significant strides with physicians, payors and patients-and expect continuing strength with the launch." Ahn continued, "We are also making steady progress in advancing our NeuVax™ and FBP cancer immunotherapy pipeline." The Full Research Report on Galena Biopharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/cad6_GALE -- Achillion Pharmaceuticals, Inc. Research Report On November 12, 2013, Achillion Pharmaceuticals, Inc. (Achillion) released its Q3 2013 results. Achillion registered net loss of $13.9 million in Q3 2013, compared to net loss of $15.3 million in Q3 2012. The Company posted basic and diluted net loss per share of $0.14 in Q3 2013, compared to basic and diluted net loss per share of $0.20 in Q3 2012. Milind S. Deshpande, Ph.D., President and CEO of Achillion, stated, "Over the next few months our priority is to advance our proprietary assets through critical milestones, including the completion of the preclinical work necessary to initiate first-in-human trials with ACH-3422, our uridine-analog nucleotide prodrug, for the potential treatment of chronic HCV." Dr. Deshpande continued, "Furthermore, we intend to engage in regulatory discussions regarding the path forward for sovaprevir, which remains on clinical hold, and in parallel, we plan to initiate early next year a drug-drug interaction study followed by a therapeutic trial to evaluate our differentiated NS5A inhibitor, ACH-3102, in combination with our macrocyclic protease inhibitor, ACH-2684." The Full Research Report on Achillion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/04a2_ACHN -- Wright Medical Group Inc. Research Report On November 12, 2013, Wright Medical Group Inc. (Wright Medical) announced its participation during the 25th Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2013, at the New York Palace Hotel in New York, New York. The Company informed that Robert Palmisano, its President and CEO, will present at 10:00 a.m. ET. Wright Medical reported that the live audio webcast and replay version will be accessible through its website under the Investor Presentations link. The Full Research Report on Wright Medical Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/1782_WMGI -- OXiGENE, Inc.Research Report On November 12, 2013, OXiGENE, Inc. (OXiGENE) released its Q3 2013 results. OXiGENE registered net loss attributable to common stock of $5.0 million in Q3 2013, compared to net loss attributable to common stock of $2.2 million in Q3 2012. OXiGENE reported basic and diluted net loss per share of $1.88 in Q3 2013, compared to basic and diluted net loss per share of $1.56 in Q3 2012. Updating on the Company's Q3 2013 performance, OXiGENE's CEO Peter Langecker, M.D., Ph.D., said, "During the third quarter, we focused on pursuing our lead development programs and ensuring that we have the resources and capabilities we need to advance our ongoing clinical and regulatory strategies, and made progress in our earlier-stage programs. We have continued to focus on identifying a registration pathway in the US for ZYBRESTAT® in ovarian cancer and, at the same time, pursuing registration for ZYBRESTAT in the EU for anaplastic thyroid cancer (ATC), utilizing the exceptional circumstances pathway for obtaining a European marketing authorization (MAA)." The Full Research Report on OXiGENE, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/f6ec_OXGN ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Quarterly Reports and Events - Research Report on Mettler-Toledo, Galena Biopharma, Achillion, Wright Medical, and OXiGENE
Press spacebar to pause and continue. Press esc to stop.